Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

KRS Pioneers Optogenetics Tools

This article was originally published in Start Up

You may also be interested in...



Optogenetics: Start-Ups Head For The Light

Optogenetics – technology to control neurons with light – has swept through basic neuroscience research. Efforts to commercialize optogenetics are complex, but a spunky group of start-ups plan to develop therapies using the technology.

Don’t Believe The Rice

After reading a paper in Cell Research that showed a microRNA produced in rice could modulate gene expression in the livers of mice that consumed it, Bill Marshall, PhD, chief scientific officer of RNA-therapeutics company miRagen Therapeutics Inc., began drawing up a business plan around the technology.

Check Again: The Problem With Reproducibility

Promising academic results prove elusive when the experiments are run again, threatening reputations and wasting industry resources. Everyone is scrambling for a fix, but is the problem as bad as it seems, and do we really need a top-down solution?

Topics

UsernamePublicRestriction

Register

LL1133148

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel